
    
      Hib-MenCY-TT = GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis
      serogroups C and Y-tetanus toxoid conjugate vaccine.

      The study will be conducted in a single blind manner up to 30 days after administration of
      the booster dose; the extended safety follow-up after the booster dose will be conducted in
      an unblinded manner.

      All subjects will receive Prevnar, M-M-R II and Varivax as study vaccines, preferencially
      co-administered with the booster dose of Hib-MenCY-TT/PedvaxHIB.

      Note: This protocol posting deals with the objectives & outcome measures for the booster
      phase of the study. The objectives & outcome measures for the primary phase are presented in
      a separate protocol posting (NCT00345579)
    
  